Clinical trial · Interventional
Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC
Cure Rates of Superficial Basal Cell Carcinoma Following 1 Versus 3 Cycles of Electrodessication & Curettage: A Randomized Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow enrollment, lack of funding
Summary
Brief summary (as posted)
This is a prospective, randomized clinical trial conducted at the Unviersity of Wisconsin (UW) Dermatology Clinic located at 1 S. Park Street, Madison, WI 53715. There are no controls. Subjects meeting eligibility criteria are randomly divided into one of two treatment groups (ED\&C x 1 cycle or ED\&C x 3 cycles) using computer generated random numbers. One cycle of ED\&C is defined according to standard technique currently employed. It involves scraping away the tumor with a curette (ring- shaped instrument) and then burning the curetted site with a small electric needle (electrodessication). During Visit 1, the surgical site is marked, local numbing medication is injected, and 1 or 3 cycles of ED\&C is/are performed by board-certified dermatologists or a dermatology resident under the direct supervision of a board certified dermatologist. All follow-up visits (3, 6, 9, and 12 months after Visit 1) include skin evaluations by the physician who performed the ED\&C. The lesion site is examined, measured, and photographed for clinical evidence of recurrence, as defined by a new lesion within the previously treated site. If there is evidence of possible tumor recurrence at the treated surgical site during Visit 2, 3, 4 or 5, then the lesion will be biopsied using a shave procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Superficial Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electrodessication & Curettage | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- ED&C times 3 cycles
- interventionNames
- Procedure: Electrodessication & Curettage
- type
- ACTIVE_COMPARATOR
- label
- ED & C times 1 cycle
- interventionNames
- Procedure: Electrodessication & Curettage
Primary outcomes (1)
- measure
- Difference in Cure Rates of Superficial BCC Following One Cycle of ED&C Versus Three Cycles of ED&C.
- timeFrame
- base line, every 3 months until 12 month completion
- description
- Clinical evidence of BCC recurrence post treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Untreated, biopsy proven superficial type basal cell carcinoma (BCC-S) on the trunk and/or extremities * Age greater than 21 * Women with childbearing potential (including those who are pregnant/lactating) * Able to provide written informed consent Exclusion Criteria: * Aggressive histology on initial biopsy (i.e. morpheaform, infiltrative, desmoplastic, or purely micronodular) * Prior history of BCC or other skin cancer at the same location * Lesion \> 2 cm * Patients with basal cell nevus syndrome * Transplant patients * Immunocompromised patients * Recurrent BCC * Greater than 2 BCC-S on the trunk and/or extremities * Prisoners * Allergy to lidocaine or epinephrine
References
Publications (0)
Data not yet available